CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

J. Rupp, Levi; Schumann, Kathrin; T. Roybal, Kole; E. Gate, Rachel; Ye, Chun; A. Lim, Wendell; Marson, Alexander

doi:10.1038/s41598-017-00462-8

Public

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Published in Scientific Reports • Apr 3, 2017

Authors:

Levi J. Rupp

Kathrin Schumann

Kole T. Roybal

Abstract

Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both opened new avenues for cancer treatment, but the clinical potential of combined disruption of inhibitory checkpoints and CAR ...

Subject

Chimeric antigen receptor

CD19

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!